Key result
MnTnHex-2-PyP5+ and doxorubicin co-treatment reduces breast cancer cell migration and invasion.
Why the study?
Little is known about the effect of manganese(III) porphyrins on metastasis in cancer treatment, necessitating understanding of their impact on this process.
Does the manganese(III) porphyrin MnTnHex-2-PyP5+ modulate intracellular ROS and cell migration in doxorubicin-treated breast cancer cells?
Does the manganese(III) porphyrin MnTnHex-2-PyP5+ modulate intracellular ROS and cell migration in doxorubicin-treated breast cancer cells?
The manganese(III) porphyrin MnTnHex-2-PyP5+ favorably modulates metastasis-related processes in doxorubicin-treated breast cancer cells in vitro.
May augment doxorubicin's effects on breast cancer cell invasion in vitro; leaves open clinical translation pending in vivo trials.
Manganese(III) porphyrins (MnPs) are superoxide dismutase (SOD) mimics with demonstrated beneficial effects in cancer treatment in combination with chemo- and radiotherapy regimens. Despite the ongoing clinical trials, little is known about the effect of MnPs on metastasis, being therefore essential to understand how MnPs affect this process. In the present work, the impact of the MnP MnTnHex-2-PyP5+ in metastasis-related processes was assessed in breast cancer cells (MCF-7 and MDA-MB-231), alone or in combination with doxorubicin (dox). The co-treatment of cells with non-cytotoxic concentrations of MnP and dox altered intracellular ROS, increasing H2O2. While MnP alone did not modify cell migration, the co-exposure led to a reduction in collective cell migration and chemotaxis. In addition, the MnP reduced the dox-induced increase in random migration of MDA-MB-231 cells. Treatment with either MnP or dox decreased the proteolytic invasion of MDA-MB-231 cells, although the effect was more pronounced upon co-exposure with both compounds. Moreover, to explore the cellular mechanisms underlying the observed effects, cell adhesion, spreading, focal adhesions, and NF-κB activation were also studied. Although differential effects were observed according to the endpoints analysed, overall, the alterations induced by MnP in dox-treated cells were consistent with a therapeutically favorable outcome.
No takes yet. Share an insight, caveat, or question.
Flórido et al. (2018) studied Breast cancer (in vitro). MnTnHex-2-PyP5+ alone or in combination with doxorubicin vs. Doxorubicin alone or untreated cells was evaluated on Metastasis-related processes (cell migration, invasion, intracellular ROS). Co-treatment of breast cancer cells with MnTnHex-2-PyP5+ and doxorubicin reduced collective cell migration, chemotaxis, and proteolytic invasion, consistent with a favorable therapeutic outcome.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: